Dosage of Cintapride
The recommended dose of cintapride (cinitapride) is 1 mg three times daily (t.i.d.) before meals for adults, with treatment duration typically 4-8 weeks for functional dyspepsia.
Standard Adult Dosing
The established dosing regimen is:
- Initial dose: 1 mg three times daily (total 3 mg/day)
- Timing: Administer before meals
- Duration: 4-8 weeks for functional dyspepsia 1, 2
This dosing was validated in large real-world studies involving over 1,000 Chinese patients with functional dyspepsia, showing 62.4% symptom improvement at 2 weeks and 90.9% at 4 weeks 1.
Dose Titration and Adjustments
Higher doses (2-4 mg per dose) have been studied but the standard 1 mg t.i.d. regimen provides optimal efficacy with better tolerability 3. Pharmacokinetic studies demonstrate approximately linear dose-proportional increases in drug exposure across the 1-4 mg range, with no significant safety concerns at higher doses 3.
After 4 weeks of treatment, clinical decision-making should be guided by response:
- If symptoms improve: Continue treatment for total 8 weeks, then consider on-demand or maintenance therapy
- If no response: Reassess diagnosis and consider alternative treatments 2
Older Adults (≥65 Years)
No specific dose reduction is required based on age alone. Treatment effects were consistent across age groups in clinical studies 2. However, monitor closely for:
- Central nervous system effects (dizziness, confusion)
- Gastrointestinal symptoms
- ECG changes
Patients under 60 years with postprandial distress syndrome showed particularly favorable responses (HR = 2.00, p = 0.019) 2.
Renal Impairment
Specific dosing recommendations for renal impairment are not established in the available evidence. The drug label and clinical studies do not provide creatinine clearance-based adjustments. Given this gap:
- Mild-moderate renal impairment: Start with standard 1 mg t.i.d., monitor closely for adverse effects
- Severe renal impairment (CrCl <30 mL/min): Consider starting at 1 mg twice daily, titrate based on tolerability
- Dialysis patients: Insufficient data; use with extreme caution
This conservative approach is warranted because pharmacokinetic data in renally impaired patients are lacking 3.
Important Safety Considerations
Monitor for ECG abnormalities, particularly QT prolongation. In the largest safety study, asymptomatic ECG abnormalities were the most common adverse event (n=8 out of 1,012 patients) 1.
Common adverse effects include:
- Diarrhea (generally transient)
- Abdominal discomfort
- Headache
- ECG changes
Contraindications (extrapolated from prokinetic class):
- Gastrointestinal obstruction or perforation
- Active gastrointestinal bleeding
- Concurrent use of QT-prolonging medications
Clinical Pearls
- Younger patients (<60 years) with lower BMI and higher education levels respond better to treatment 2
- On-demand regimens after initial 4-week treatment show comparable efficacy to continuous maintenance (HR = 8.54 vs 9.18) with reduced drug exposure 2
- Treatment response at 4 weeks predicts 8-week outcomes, making this a reasonable decision point for continuation 2
- The drug shows efficacy not only in functional dyspepsia but also in overlapping conditions (GERD, IBS, functional constipation), though pure FD responds better than overlapping syndromes 1